Table 2.

Serious and non-serious adverse events (N = 9)

	N (%)
Serious adverse events*	0 (0)
Other adverse events
Liver dysfunction	0 (0)
Thrombocytopenia	0 (0)
PPHN	1 (13)
DIC	0 (0)
Sepsis	1 (13)
Renal dysfunction	0 (0)
Hypertension	0 (0)
Polycythemia	0 (0)

^*Serious adverse events included death, severe cardiopulmonary collapse, thrombosis of a major vessel, and unexpected events that were likely related to the study treatment. DIC: disseminated intravascular coagulation; PPHN: persistent pulmonary hypertension of the newborn